Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 14/20 | 0.58 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5697177 | 0.90 | MMP13 (0.71) | MMP13SLC22A8MAPK10 | |
| SCHEMBL5697153 | 0.86 | MMP13 (0.68) | MMP13SLC22A8 | |
| SCHEMBL8345034 | 0.85 | CRHBP (0.41) | MMP13CRHBPCRHR2RECQLMAPK10 | |
| SCHEMBL5697258 | 0.85 | MMP13 (0.57) | MMP13SLC22A8GABRA1GABRG2GABRB3 | |
| SCHEMBL6167249 | 0.84 | MMP13 (0.56) | MMP13SLC22A8PDPK1 | |
| SCHEMBL6247584 | 0.84 | MMP13 (0.52) | MMP13SLC22A8GABRA1GABRG2GABRB3 | |
| SCHEMBL5697180 | 0.84 | MMP13 (0.60) | MMP13GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL6177228 | 0.83 | MMP13 (0.43) | MMP13SLC22A8GABRA1GABRG2GABRB3 | |
| SCHEMBL6286878 | 0.83 | MMP13 (0.50) | MMP13SLC22A8GABRA1GABRG2GABRB3 | |
| SCHEMBL6704286 | 0.82 | EPHX2 (0.44) | MMP13CRHBPCRHR2RECQLMAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1680125-A1 | COMBINATION OF AN ALLOSTERIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 AND A LIGAND TO AN ALPHA-2-DELTA RECEPTOR | Warner-Lambert Company LLC (US) | 2006-07-19 | — | — | EP | disclosed |
| EP-1530472-A1 | ISOQUINOLINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2005-05-18 | — | — | EP | disclosed |
| WO-2005002585-A1 | COMBINATION OF AN ALLOSTERIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 AND A LIGAND TO AN ALPHA-2-DELTA RECEPTOR | WARNER-LAMBERT COMPANY LLC (US) | 2005-01-13 | — | — | WO | disclosed |
| US-20050004177-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor | WARNER-LAMBERT COMPANY LLC | 2005-01-06 | — | — | US | disclosed |
| US-20040044000-A1 | Isoquinoline derivatives as matrix metalloproteinase inhibitors | BUNKER AMY MAE (US) | 2004-03-04 | — | — | US | disclosed |
| WO-2004014379-A1 | ISOQUINOLINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004177-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor | MMP13, MMP10, MMP11 | MMP13 1/4885SLC22A8 1909/4885GABRA1 654/4885 |
| US-20040044000-A1 | Isoquinoline derivatives as matrix metalloproteinase inhibitors | MMP1, MMP13, MMP9 | MMP13 2/4885SLC22A8 1532/4885GABRA1 4743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.